前列地尔注射液治疗慢性重型肝炎的临床观察(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 探讨前列地尔注射液对慢性重型肝炎的临床效果及安全性。 方法 将慢性重型肝炎患者60例按入院顺序随机分为对照组和观察组，每组各30例，对照组给予护肝、退黄及支持治疗等常规的内科综合治疗；观察组在对照组治疗基础上加用前列地尔注射液5 μg加10 mL生理盐水，1次/d。疗程均为4周。 结果 治疗慢性重型肝炎的总有效率：观察组为70.0%，对照组为43.3%，两组比较差异有统计学意义(P < 0.05)；在血清总胆红素水平、丙氨酸氨基转移酶、凝血酶原活动度、并发症的发生率等方面治疗后观察组与对照组比较，差异有统计学意义(P < 0.05)。 结论 前列地尔注射液治疗慢性重型肝炎安全性高，疗效较好，可作为重症肝炎治疗的有效药物之一。
[关键词] 前列地尔；重型肝炎；治疗
[中图分类号] R575.2 [文献标识码] A [文章编号] 1673-7210(2012)02(a)-0073-02
Clinical observation of severe chronic hepatitis treated with Alprostadil Injection
LI Qun1 ZHU Ping2
1.Department of Gastroenterology, the General Hospital of Ji'nan Military Region, Shandong Province, Ji'nan 250031, China; 2.Weifang Medical College, Shandong Province, Weifang 261053, China
[Abstract] Objective To explore the therapeutic effect and safety of Alprostadil Injection in the treatment of severe chronic hepatitis. Methods 60 patients with severe chronic hepatitis were randomly divided into the control group and the observation group according to the order in hospital, with each group of 30 cases, the control group was given conventional therapeutic: hepatinica, jaundice treating drugs and supportive treatment, and so on; on the basis of the control group, the observation group was given Alprostadil Injection 5 μg plus 10 mL NS, one time a day. The treatment course was 4 weeks. Results The total effective rate of severe chronic hepatitis: the observation group was 70.0%, the control group was 43.3%, there was significant difference between the two groups (P < 0.05). After treatment, there was significant difference in the level of TBIL, ALT, PTA and the incidence rate of complications between the two groups (P < 0.05). Conclusion Alprostadil Injection is a safe and good drug in the treatment of severe chronic hepatitis. It can be used to treat severe chronic hepatitis as an effective drug.
[Key words] Alprostadil; Severe hepatitis; Treatment
慢性重型肝炎是在慢性肝炎或肝硬化基础上以肝细胞坏死、肝功能衰竭为特征的疾病，预后差、死亡率高，临床表现极度乏力、频繁呕吐、腹胀等中毒症状，黄疸进行性加重，胆酶分离[血清胆红素(TBIL)迅速上升，丙氨酸氨基转移酶(ALT)迅速下降]，凝血酶原活动度(PTA)<40%，白蛋白降低等。临床上以支持和对症疗法为基础，促进肝细胞再生，预防和治疗各种并发症的综合性治疗为原则。前列地尔注射液(商品名：曼新妥)对病变部位靶向治疗，能扩张肝病变血管，有效防止和减轻肝细胞坏死，促进肝细胞再生[1-3]，因此，本研究应用两种不同的方法将2009年1月～2010年12月入济南军区总医院消化科治疗的60例慢性重型肝炎患者的临床疗效和安全性进行分析 ......
您现在查看是摘要介绍页，详见PDF附件(1755kb)。